Bye, bye Peter Dolan, hello Karen Katen???
The Wall Street Journal writes, During his five years as chief executive of Bristol-Myers Squibb Co., Peter Dolan has overcome a series of controversies, ranging from a financial scandal to research failures and questionable deals.
But some shareholders aren't inclined to let Mr. Dolan off the hook for the company's latest setback: the loss of marketing exclusivity over its best-selling drug, the blood thinner Plavix, five years ahead of schedule.
"He's either the most unlucky guy in the world or he's just not suitable to be CEO," says Thomas Cooper, a former stockbroker in Atlanta whose family owns more than 125,000 Bristol-Myers shares, valued at $2.6 million.
Bye, bye Dolan, hello Karen Katen???
You heard it here first!